Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. BMY has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
BMY stock price ended at $48.28 on Friday, after rising0.9%
The Bristol-Myers Squibb Co stock price increased by 0.9% on the last trading day (30 May 2025), rising from 47.87 to 48.28. Throughout the last trading session, the stock experienced a fluctuation of 2.22% , ranging from a day low of $47.3 to a day high of 48.35. The price has declined in 2 of the last 10 days, resulting in a total change of 5.39% during this period. On the last day, trading volume decrease by 10.27M shares, with the rising prices. This could serve as an early warning, indicating that risk may slightly increase in the coming days. In total, 20.76M shares were traded, amounting to approximately 1.00B.
BMY Technical Signals
BMY(Bristol-Myers Squibb Co Corp) has 3 buy signals and 5 sell signals now. The current trend is consolidation starting from 2025-05-22. The total price change during this trend is +2.66%. Recently, the price has increased significantly with an increase in volume, indicating a strong bullish signal. The average turnover of BMY over the last 5 trading days is 617.79M. Overall, the technical indicator signals lean more toward a Bearish outlook in the mid-term.
BMY Moving Average Analysis
Bristol-Myers Squibb Co's overall moving average trend leans more bullish as of Saturday, May 31, 2025, with 2 negative signals and 2 positive signal. In the mid-term, the SMA_20 being below the SMA_60 signals a strong bearish trend. There will be some resistance from the lines at $48.716233333333335, and $49.690333333333335. A break-up above any of these levels will issue buy signals. There will be some support from the lines at $45.56443333333333, and $44.59033333333333. A break-down below any of these levels will issue sell signals.
BMY Short Selling Analysis
The short sale ratio of Bristol-Myers Squibb Co(BMY) as of 27 May 2025 is 9.00%, dropping from last trading day. With decreasing price from 46.85 to 46.89. The short sell activity indicate that short sellers may be experiencing short cover.
Technical Signal
Technical Signals Summary
Sell
Sell
5
Buy
3
Moving Average
Swing
Positive
Stock Price Above SMA_5
Short Term
Positive
SMA_5 Above SMA_20
Mid Term
Negative
SMA_20 Below SMA_60
Long Term
Negative
SMA_60 Below SMA_200
Short Selling
Close Price
Short Sale Ratio
Short Sale Volume
3 Bullish Signals
3 Bullish Signals
When Value satisfies Signal, Indicator signals Bullish
Indicators
Signal
Value
Meaning
Momentum (10 days)
MOM_10 > 0
2.47
Bullish
Closing price
close > fibonacci_R1
48.28
Bullish
Moving Average
5-day SMA crosses above 20-day SMA
--
Bullish
5 Bearish Signals
5 Bearish Signals
When Value satisfies Signal, Indicator signals Bearish
Indicators
Signal
Value
Meaning
Stochastic Oscillator %K (14, 3, 3)
STOCHk_14_3_3 > 80
83.801
Bearish
Awesome Oscillator (5, 34)
AO_5_34 < 0
-0.963
Bearish
Moving Average Convergence Divergence (12, 26, 9)
MACD_12_26_9 < 0
-0.87
Bearish
Stochastic RSI %K (14, 14, 3, 3)
STOCHRSIk_14_14_3_3 > 80
94.455
Bearish
Williams %R (14 days)
WILLR_14 > -20
-3.062
Bearish
BMY Price Prediction & Forecast by Similar Chart Analysis
Based on historical patterns and backtesting of stocks with similar movements to Bristol-Myers Squibb Co(BMY), our algorithm predicts BMY's 1-month price at $47.24, with an 1.04%upwardshift. Using a similarity score up to 96.80%and other factors, This forecast updates weekly, adjusting for significant deviations.
Similar Chart
The price prediction chart for Bristol-Myers Squibb Co (BMY.N) stock, as of Sunday, May 18, 2025 , forecasts a 1.04% change over the next month, based on its high correlation with GEHC.O stock patterns. The similarity between their price movements over the analyzed periods is 96.8%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
BMY
Future prediction
Up: 1.04%
GEHC
Up: 1.04%Similarity: 96.8%
Name
Similarity
Up/Down
GEHC.O
96.80%
+1.04%
INTS.O
96.42%
+58.75%
PEN.N
96.30%
+31.54%
SANW.O
95.94%
-10.23%
FBIO.O
95.86%
+5.56%
FATE.O
95.82%
+5.97%
UWMC.N
95.68%
-3.95%
CVGI.O
95.50%
+15.14%
KALV.O
95.43%
-24.18%
COHN.A
95.37%
+29.84%
BMY Seasonality Analysis
Based on BMY's historical stock price data across all years, the probability of a positive return in May is36.36%, suggesting it maynotbe an ideal month to invest in BMY. In contrast,Novemberoffers the highest probability of positive returns at80.00%, making it a potentially strong month for investment.
However, this is only a prediction based on one method, and a comprehensive assessment of the stock's future trend should consider additional factors. Our final stock price commentary incorporates three main evaluation dimensions: technical signals, Moving Average trends, and similar chart pattern matching, with the first two dimensions carrying the primary weight to ensure a more robust and accurate forecast.
Monthly Seasonality
The radar chart shows that buying Bristol-Myers Squibb Co (BMY.N) stock in November has the highest probability of a positive return (80.00%), while April has the lowest probability (36.36%).
Performance Seasonality
The chart shows Bristol-Myers Squibb Co. (BMY)'s annual stock price return for the past three years, helping you analyze price trends and identify recurring trends on an annual basis.
Should I buy Bristol-Myers Squibb Co (BMY.N) stock?
Based on our evaluation of the five key dimensions—Technical Signals, Moving Average trends, Short Sell Data, Similar Chart Pattern Matching and Seasonality Analysis—we have identified the following insights. BMY has several negative signals and is within a falling trend, so we believe it will perform weakly in the next couple of days or weeks. We therefore hold a negative evaluation of this stock. Our analysis conclusion for this stock is a Strong Sell candidate.
Which months have the highest win rate for buying Bristol-Myers Squibb Co (BMY.N) stock in a year?
The radar chart shows that buying Bristol-Myers Squibb Co (BMY.N) stock in November has the highest probability of a positive return (80.00%), while April has the lowest probability (36.36%).
How has Bristol-Myers Squibb Co. (BMY)'s stock price performed over the past three years?
BMY's stock price fell by -26.46% in 2023,increased by 12.62% in 2024, and went down by 13.11% in 2025.
Which bull technical signals does BMY have?
Bullish technical signals of BMY include: MOM_10 > 0, close > fibonacci_R1, 5-day SMA crosses above 20-day SMA.
Is BMY a buy based on overall technical signals summary?
BMY has 3 buy signals and 5 sell signals now. Overall the technical rating for BMY is Sell . Note that market conditions change all the time. In addition to technical ratings, keep an eye on the Valuation Level of BMY.
What is the trend of Bristol-Myers Squibb Co (BMY)'s moving average?
Bristol-Myers Squibb Co's overall moving average trend leans more bullish as of May 31 2025, with 2 negative signals and 2 positive signal.
What is price prediction for BMY stock next month?
The price prediction chart for Bristol-Myers Squibb Co (BMY.N) stock, as of May 18 2025, forecasts a 1.04% change over the next month, based on its high correlation with GEHC stock patterns. The similarity between their price movements over the analyzed periods is 96.8%. The right panel lists other stocks with similar price patterns. This prediction is updated every week.
What is price prediction 2025 for BMY Stock?
BMY stock is predicted to reach **$58** by end of 2025.
Reason: Attractive forward P/E of 7.09, strong pipeline growth, and 5.34% dividend yield.
What is price prediction 2030 for BMY Stock?
Bristol Myers Squibb (BMY) stock is predicted to reach **$75 by 2030**, driven by its undervalued status, strong financial performance, and promising pipeline growth. The stock currently trades at a forward P/E of 7.2, offering significant upside potential.